Andreas Hougaard Laustsen-Kiel

List of Publications by Year
in descending order

70 papers	2,516 citations	172457 29 h-index	214800 47 g-index
85 all docs	85 docs citations	85 times ranked	1656 citing authors

#	Article	IF	Citations
1	The challenges with developing therapeutic monoclonal antibodies for pandemic application. Expert Opinion on Drug Discovery, 2022, 17, 5-8.	5.0	2
2	The rise of genomics in snake venom research: recent advances and future perspectives. GigaScience, 2022, 11, .	6.4	17
3	Genomic Confirmation of the P-IIIe Subclass of Snake Venom Metalloproteinases and Characterisation of Its First Member, a Disintegrin-Like/Cysteine-Rich Protein. Toxins, 2022, 14, 232.	3.4	6
4	Orally active bivalent VHH construct prevents proliferation of F4+ enterotoxigenic Escherichia coli in weaned piglets. IScience, 2022, 25, 104003.	4.1	6
5	Synthetic antibodies block receptor binding and currentâ€inhibiting effects of Î±â€cobratoxin from Naja kaouthia. Protein Science, 2022, 31, e4296.	7.6	5
6	Black-necked spitting cobra (Naja nigricollis) phospholipases A2 may cause Trypanosoma brucei death by blocking endocytosis through the flagellar pocket. Scientific Reports, 2022, 12, 6394.	3.3	3
7	In Vivo Neutralization of Myotoxin II, a Phospholipase A₂ Homologue from Bothrops asper Venom, Using Peptides Discovered via Phage Display Technology. ACS Omega, 2022, 7, 15561-15569.	3.5	3
8	Advances in antibody phage display technology. Drug Discovery Today, 2022, 27, 2151-2169.	6.4	62
9	In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom. MAbs, 2022, 14, .	5.2	22
10	Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery. Trends in Biotechnology, 2021, 39, 1263-1273.	9.3	74
11	Snakebite Envenoming Diagnosis and Diagnostics. Frontiers in Immunology, 2021, 12, 661457.	4.8	46
12	Unraveling the structure and function of CdcPDE: A novel phosphodiesterase from Crotalus durissus collilineatus snake venom. International Journal of Biological Macromolecules, 2021, 178, 180-192.	7.5	7
13	Crotalus Durissus Ruruima: Current Knowledge on Natural History, Medical Importance, and Clinical Toxinology. Frontiers in Immunology, 2021, 12, 659515.	4.8	8
14	Clinical management of snakebite envenoming: Future perspectives. Toxicon: X, 2021, 11, 100079.	2.9	22
15	Terrestrial venomous animals, the envenomings they cause, and treatment perspectives in the Middle East and North Africa. PLoS Neglected Tropical Diseases, 2021, 15, e0009880.	3.0	11
16	Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins. Frontiers in Bioengineering and Biotechnology, 2021, 9, 811905.	4.1	16
17	Discovery of cross-reactive and recyclable human monoclonal antibodies for new recombinant antivenoms. Toxicon, 2020, 177, S38.	1.6	0
18	Discovery and evaluation of monoclonal antibodies for stratification of venoms from brazilian Bothrops, Crotalus, and Lachesis species. Toxicon, 2020, 177, S38.	1.6	0

#	Article	IF	Citations
19	Discovery of a Recombinant Human Monoclonal Immunoglobulin G Antibody Against Î±-Latrotoxin From the Mediterranean Black Widow Spider (Latrodectus tredecimguttatus). Frontiers in Immunology, 2020, 11, 587825.	4.8	7
20	Cost of Manufacturing for Recombinant Snakebite Antivenoms. Frontiers in Bioengineering and Biotechnology, 2020, 8, 703.	4.1	26
21	Peptide Inhibitors of the Î±-Cobratoxinâ€“Nicotinic Acetylcholine Receptor Interaction. Journal of Medicinal Chemistry, 2020, 63, 13709-13718.	6.4	15
22	Current Knowledge on Snake Dry Bites. Toxins, 2020, 12, 668.	3.4	34
23	Novel Snakebite Therapeutics Must Be Tested in Appropriate Rescue Models to Robustly Assess Their Preclinical Efficacy. Toxins, 2020, 12, 528.	3.4	24
24	Unity Makes Strength: Exploring Intraspecies and Interspecies Toxin Synergism between Phospholipases A2 and Cytotoxins. Frontiers in Pharmacology, 2020, 11, 611.	3.5	29
25	Scorpion Venom: Detriments and Benefits. Biomedicines, 2020, 8, 118.	3.2	62
26	Identification of cross-reactive human single-chain variable fragments against phospholipases A2 from Lachesis muta and Bothrops spp venoms. Toxicon, 2020, 184, 116-121.	1.6	8
27	Causes and Consequences of Snake Venom Variation. Trends in Pharmacological Sciences, 2020, 41, 570-581.	8.7	185
28	Editorial: Novel Immunotherapies Against Envenomings by Snakes and Other Venomous Animals. Frontiers in Immunology, 2020, 11, 1004.	4.8	7
29	An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies. Scientific Reports, 2020, 10, 10765.	3.3	34
30	An interactive database for the investigation of high-density peptide microarray guided interaction patterns and antivenom cross-reactivity. PLoS Neglected Tropical Diseases, 2020, 14, e0008366.	3.0	10
31	Do Antibiotics Potentiate Proteases in Hemotoxic Snake Venoms?. Toxins, 2020, 12, 240.	3.4	5
32	Chronic kidney failure following lancehead bite envenoming: a clinical report from the Amazon region. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2020, 26, e20200083.	1.4	5
33	How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?. Expert Opinion on Drug Discovery, 2019, 14, 1103-1112.	5.0	23
34	History of Envenoming Therapy and Current Perspectives. Frontiers in Immunology, 2019, 10, 1598.	4.8	77
35	Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy. Frontiers in Immunology, 2019, 10, 2090.	4.8	104
36	Toxin Neutralization Using Alternative Binding Proteins. Toxins, 2019, 11, 53.	3.4	30

#	Article	IF	Citations
37	Discovery of human antibodies against forest cobra toxins. Toxicon, 2019, 158, S51-S52.	1.6	0
38	Engineering and design considerations for next-generation snakebite antivenoms. Toxicon, 2019, 167, 67-75.	1.6	43
39	Design of scfab-based chimeric antibodies against Bothrops asper pi-metalloproteinase. Toxicon, 2019, 158, S41.	1.6	0
40	Harnessing phage display technology for discovery of human IgGs targeting clinically relevant toxins from the venom of the Central American coral snake (Micrurus nigrocinctus). Toxicon, 2019, 158, S45.	1.6	0
41	Harnessing human monoclonal antibodies for neutralisation of dendrotoxins in a murine model. Toxicon, 2019, 159, S14.	1.6	0
42	Protease Activity Profiling of Snake Venoms Using High-Throughput Peptide Screening. Toxins, 2019, 11, 170.	3.4	11
43	Recombinant antivenom against the venom of Dendroaspis polylepis. Toxicon, 2019, 158, S43.	1.6	0
44	Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon, 2018, 146, 151-175.	1.6	125
45	Guiding recombinant antivenom development by omics technologies. New Biotechnology, 2018, 45, 19-27.	4.4	44
46	Innovative Immunization Strategies for Antivenom Development. Toxins, 2018, 10, 452.	3.4	58
47	Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims. Toxins, 2018, 10, 534.	3.4	64
48	Antibody Cross-Reactivity in Antivenom Research. Toxins, 2018, 10, 393.	3.4	33
49	In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nature Communications, 2018, 9, 3928.	12.8	73
50	Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms. Toxins, 2018, 10, 309.	3.4	21
51	Toxin-centric development approach for next-generation antivenoms. Toxicon, 2018, 150, 195-197.	1.6	16
52	Snake Venomics Display: An online toolbox for visualization of snake venomics data. Toxicon, 2018, 152, 60-64.	1.6	9
53	Basics of Antibody Phage Display Technology. Toxins, 2018, 10, 236.	3.4	142
54	Recent Advances in Next Generation Snakebite Antivenoms. Tropical Medicine and Infectious Disease, 2018, 3, 42.	2.3	45

#	Article	IF	Citations
55	Pitfalls to avoid when using phage display for snake toxins. Toxicon, 2017, 126, 79-89.	1.6	14
56	High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction. Toxicon, 2017, 138, 151-158.	1.6	12
57	Exploring the venom of the forest cobra snake: Toxicovenomics and antivenom profiling of Naja melanoleuca. Journal of Proteomics, 2017, 150, 98-108.	2.4	85
58	Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?. PLoS Neglected Tropical Diseases, 2017, 11, e0005361.	3.0	64
59	Cross-recognition of a pit viper (Crotalinae) polyspecific antivenom explored through high-density peptide microarray epitope mapping. PLoS Neglected Tropical Diseases, 2017, 11, e0005768.	3.0	17
60	Exploration of immunoglobulin transcriptomes from mice immunized with three-finger toxins and phospholipases A₂from the Central American coral snake,Micrurus nigrocinctus. PeerJ, 2017, 5, e2924.	2.0	32
61	Biotechnological Trends in Spider and Scorpion Antivenom Development. Toxins, 2016, 8, 226.	3.4	55
62	Snakebites: costing recombinant antivenoms. Nature, 2016, 538, 41-41.	27.8	23
63	Toxin synergism in snake venoms. Toxin Reviews, 2016, 35, 165-170.	3.4	43
64	High-throughput immuno-profiling of mamba (Dendroaspis) venom toxin epitopes using high-density peptide microarrays. Scientific Reports, 2016, 6, 36629.	3.3	33
65	Toxicovenomics and antivenom profiling of the Eastern green mamba snake (Dendroaspis angusticeps) Tj ETQq1 1 0.784314 rgBT /Ove	2.4	70
66	From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. Current Pharmaceutical Design, 2016, 22, 5270-5293.	1.9	101
67	Unveiling the nature of black mamba (Dendroaspis polylepis) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom development. Journal of Proteomics, 2015, 119, 126-142.	2.4	102
68	Danger in the reef: Proteome, toxicity, and neutralization of the venom of the olive sea snake, Aipysurus laevis. Toxicon, 2015, 107, 187-196.	1.6	38
69	Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins. Toxicon, 2015, 99, 23-35.	1.6	60
70	Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score. Toxicon, 2015, 104, 43-45.	1.6	75